Lumito (LUMITO) Q4 2024 earnings summary

Executive summary

• Focus on commercializing Scizys, strengthening brand, and driving revenue generation; strategic partnerships and cost-reduction initiatives implemented in Q4 2024.

• Key milestones include a 94% subscription rate for warrants, loan refinancing, and a strategic partnership with Truly Labs.

• Scizys technology offers high sensitivity, quantitative biomarker analysis, and dual-layer imaging, targeting research and pharma markets.

Financial highlights

• Q4 2024 net sales reached 79 TSEK (0 TSEK Q4 2023); full-year 2024 net sales were 97 TSEK (0 TSEK 2023).

• Q4 2024 net loss after tax was -15,476 TSEK (-5,777 TSEK Q4 2023); full-year net loss after tax was -41,564 TSEK (-25,804 TSEK 2023).

• Cash flow from operations after working capital changes was -6,213 TSEK in Q4 (-5,480 TSEK Q4 2023) and -28,027 TSEK for the year (-25,315 TSEK 2023).

• Cash and cash equivalents at year-end were 21,592 TSEK (22,454 TSEK 2023).

• Equity at year-end was 92,792 TSEK (103,159 TSEK 2023); solidity 83% (85%).

Outlook and guidance

• Continued focus on commercializing Scizys, expanding strategic partnerships, and scaling through CRO collaborations.

• No dividend proposed for 2024; emphasis on financial sustainability and growth.